{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:08:06Z","timestamp":1768550886319,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006436","name":"celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s13555-021-00658-x","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T17:02:46Z","timestamp":1639587766000},"page":"203-221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO"],"prefix":"10.1007","volume":"12","author":[{"given":"Kristian","family":"Reich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Korge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Magnolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Manasterski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Schwichtenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Staubach-Renz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josefine","family":"Roemmler-Zehrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie N\u00fanez","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Lorenz-Baath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,15]]},"reference":[{"key":"658_CR1","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.cyto.2014.12.014","volume":"73","author":"J Baliwag","year":"2015","unstructured":"Baliwag J, Barnes DH, Johnston A. Cytokines in psoriasis. Cytokine. 2015;73:342\u201350.","journal-title":"Cytokine"},{"key":"658_CR2","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","volume":"70","author":"MG Lebwohl","year":"2014","unstructured":"Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et\u00a0al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70:871\u201381.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 2","key":"658_CR3","first-page":"18","volume":"64","author":"RG Langley","year":"2005","unstructured":"Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):18\u201323.","journal-title":"Ann Rheum Dis"},{"key":"658_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12589","volume":"31","author":"JF Merola","year":"2018","unstructured":"Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31:e12589.","journal-title":"Dermatol Ther"},{"key":"658_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","volume":"303","author":"U Mrowietz","year":"2011","unstructured":"Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, et\u00a0al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1\u201310.","journal-title":"Arch Dermatol Res"},{"key":"658_CR6","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/bjd.17403","volume":"181","author":"M Augustin","year":"2019","unstructured":"Augustin M, Sommer R, Kirsten N, Danckworth A, Radtke MA, Reich K, et\u00a0al. Topology of psoriasis in routine care\u2014results from a high-resolution analysis in 2009 patients. Br J Dermatol. 2019;181:358\u201365.","journal-title":"Br J Dermatol"},{"key":"658_CR7","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1007\/s00105-019-4411-y","volume":"70","author":"R Sommer","year":"2019","unstructured":"Sommer R, Augustin M, Mrowietz U, Topp J, Schafer I, von Spreckelsen R. Perception of stigmatization in people with psoriasis \u2013 qualitative analysis from the perspective of patients, relatives and healthcare professionals. Hautarzt. 2019;70:520\u20136.","journal-title":"Hautarzt"},{"key":"658_CR8","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","volume":"149","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003\u20132011. JAMA Dermatol. 2013;149:1180\u20135.","journal-title":"JAMA Dermatol"},{"key":"658_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","volume":"65","author":"A Menter","year":"2011","unstructured":"Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et\u00a0al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137\u201374.","journal-title":"J Am Acad Dermatol"},{"key":"658_CR10","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s40265-015-0439-1","volume":"75","author":"ED Deeks","year":"2015","unstructured":"Deeks ED. Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. 2015;75:1393\u2013403.","journal-title":"Drugs"},{"key":"658_CR11","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","volume":"83","author":"P Schafer","year":"2012","unstructured":"Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583\u201390.","journal-title":"Biochem Pharmacol"},{"key":"658_CR12","unstructured":"Otezla. Summary of product characteristics. Breda: Amgen Europe B.V.; 2020."},{"key":"658_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et\u00a0al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM 1]). J Am Acad Dermatol. 2015;73:37\u201349.","journal-title":"J Am Acad Dermatol"},{"key":"658_CR14","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et\u00a0al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. 2015;173:1387\u201399.","journal-title":"Br J Dermatol"},{"key":"658_CR15","first-page":"801","volume":"16","author":"B Strober","year":"2017","unstructured":"Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson JM, Chen R, et\u00a0al. Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: week 16 results from the UNVEIL study. J Drugs Dermatol. 2017;16:801\u20138.","journal-title":"J Drugs Dermatol JDD"},{"key":"658_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/jdv.14738","volume":"32","author":"K Reich","year":"2018","unstructured":"Reich K, Gooderham M, Bewley A, Green L, Soung J, Petric R, et\u00a0al. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study. J Eur Acad Dermatol Venereol. 2018;32:397\u2013402.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"658_CR17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jaad.2020.01.072","volume":"83","author":"AS Van Voorhees","year":"2020","unstructured":"Van Voorhees AS, Gold LS, Lebwohl M, Strober B, Lynde C, Tyring S, et\u00a0al. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. J Am Acad Dermatol. 2020;83:96\u2013103.","journal-title":"J Am Acad Dermatol"},{"key":"658_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/jdv.15878","volume":"34","author":"M Masson Regnault","year":"2020","unstructured":"Masson Regnault M, Casta\u00f1eda-Sanabria J, Diep Tran MHT, Beylot-Barry M, Bachelez H, Beneton N, et\u00a0al. Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ. J Eur Acad Dermatol Venereol. 2020;34:293\u2013300.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"658_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/jdv.16431","volume":"35","author":"M Augustin","year":"2021","unstructured":"Augustin M, Kleyn CE, Conrad C, Sator PG, Stahle M, Eyerich K, et\u00a0al. Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study. J Eur Acad Dermatol Venereol. 2021;35:123\u201334.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"658_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2340\/00015555-1543","volume":"93","author":"A Reich","year":"2013","unstructured":"Reich A, Medrek K, Stander S, Szepietowski JC. Determination of minimum clinically important difference (MCID) of visual analogue scale (VAS): in which direction should we proceed? [abstract IL26]. Acta Derm Venereol. 2013;93:609\u201310.","journal-title":"Acta Derm Venereol"},{"key":"658_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/1203475416676030","volume":"21","author":"JN Mayba","year":"2017","unstructured":"Mayba JN, Gooderham MJ. Real-world experience with apremilast in treating psoriasis. J Cutan Med Surg. 2017;21:145\u201351.","journal-title":"J Cutan Med Surg"},{"key":"658_CR22","first-page":"11731179","volume":"23","author":"E Papadavid","year":"2018","unstructured":"Papadavid E, Rompoti N, Theodoropoulos K, Kokkalis G, Rigopoulos D. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2018;23:1173\u20131179.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"658_CR23","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1080\/09546634.2018.1528326","volume":"30","author":"MLF Knuckles","year":"2019","unstructured":"Knuckles MLF, Levi E, Soung J. Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast. J Dermatol Treat. 2019;30:430\u20134.","journal-title":"J Dermatol Treat."},{"key":"658_CR24","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/jdv.14598","volume":"32","author":"I Vujic","year":"2018","unstructured":"Vujic I, Herman R, Sanlorenzo M, Posch C, Monshi B, Rappersberger K, et\u00a0al. Apremilast in psoriasis\u2014a prospective real-world study. J Eur Acad Dermatol Venereol. 2018;32:254\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"658_CR25","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/ced.12805","volume":"41","author":"JF Merola","year":"2016","unstructured":"Merola JF, Li T, Li WQ, Cho E, Qureshi AA. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol. 2016;41:486\u20139.","journal-title":"Clin Exp Dermatol"},{"key":"658_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12895-020-00099-7","volume":"20","author":"A Egeberg","year":"2020","unstructured":"Egeberg A, See K, Garrelts A, Burge R. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort. BMC Dermatol. 2020;20:3.","journal-title":"BMC Dermatol"},{"key":"658_CR27","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1111\/bjd.17128","volume":"179","author":"M Augustin","year":"2018","unstructured":"Augustin M, Langenbruch A, Gutknecht M, Reich K, Korber A, Maassen D, et\u00a0al. Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management. Br J Dermatol. 2018;179:1385\u201391.","journal-title":"Br J Dermatol"},{"key":"658_CR28","first-page":"48","volume":"12","author":"M Augustin","year":"2014","unstructured":"Augustin M, Spehr C, Radtke MA, Boehncke WH, Luger T, Mrowietz U, et\u00a0al. German psoriasis registry PsoBest: objectives, methodology and baseline data. J Dtsch Dermatol Ges. 2014;12:48\u201357.","journal-title":"J Dtsch Dermatol Ges"},{"key":"658_CR29","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/1203475418755982","volume":"22","author":"A Ighani","year":"2018","unstructured":"Ighani A, Georgakopoulos JR, Zhou LL, Walsh S, Shear N, Yeung J. Efficacy and safety of apremilast monotherapy for moderate to severe psoriasis: retrospective study. J Cutan Med Surg. 2018;22:290\u20136.","journal-title":"J Cutan Med Surg"},{"key":"658_CR30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/jdv.14015","volume":"31","author":"K Reich","year":"2017","unstructured":"Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, et\u00a0al. The efficacy and safety of apremilast, etanercept, and placebo, in patients with moderate to severe plaque psoriasis: 52-week results from a phase 3b, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2017;31:507\u201317.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"658_CR31","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s00105-019-4396-6","volume":"70","author":"A Pinter","year":"2019","unstructured":"Pinter A, Beigel F, K\u00f6rber A, Homey B, Beissert S, Gerdes S, et\u00a0al. Gastrointestinal side effects of apremilast: characterization and management. Hautarzt. 2019;70:354\u201362.","journal-title":"Hautarzt"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00658-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-021-00658-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00658-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T03:16:34Z","timestamp":1642734994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-021-00658-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,15]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["658"],"URL":"https:\/\/doi.org\/10.1007\/s13555-021-00658-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,15]]},"assertion":[{"value":"11 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}